Copeptin as a biomarker in heart failure
Louise Balling1, Finn Gustafsson
1Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Insights
Copeptin shows promise as a prognostic marker in heart failure (HF), potentially outperforming other biomarkers. Further research is needed to define its role in risk stratification and guiding therapy.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Heart failure (HF) is characterized by increased neurohormonal activation.
- Copeptin, a marker for proarginine vasopressin, has established prognostic value across various diseases.
- Elevated copeptin in HF correlates with adverse outcomes, including mortality and hospitalization risk, and HF severity.
Purpose of the Study:
- To evaluate the prognostic value of copeptin in heart failure.
- To compare copeptin with established biomarkers like BNP and NT-proBNP.
- To explore the potential role of copeptin in risk stratification and biomarker-guided therapy for HF.
Main Methods:
- Observational studies analyzing plasma copeptin levels in heart failure patients.
- Comparison of copeptin's prognostic performance against clinical variables and natriuretic peptides (BNP, NT-proBNP).
- Assessment of copeptin in patients hospitalized for HF or myocardial infarction (MI).
Main Results:
- Elevated plasma copeptin in HF is linked to increased mortality and hospitalization risk.
- Copeptin may provide additional prognostic information beyond traditional predictors in HF.
- Copeptin demonstrated superiority over BNP and NT-proBNP in HF patients post-discharge following HF or MI hospitalization.
Conclusions:
- Copeptin is a significant prognostic marker in heart failure.
- It may offer advantages over current biomarkers for predicting adverse outcomes in HF.
- Further randomized trials are essential to clarify copeptin's optimal clinical application in HF management, including risk stratification and targeted therapy.
Abstract:
Increased neurohormonal activation is a key feature of heart failure (HF). Copeptin is a surrogate marker for proarginine vasopressin and the prognostic value of copeptin has been reported for multiple disease states of both nonvascular and cardiovascular etiology. Elevated plasma copeptin in HF has been associated with adverse outcomes such as increased mortality, risk of hospitalization and correlates with the severity of HF. Copeptin may add prognostic information to already established predictors such as clinical variables and natriuretic peptides in HF. In addition, copeptin has been found to be a superior marker when compared with BNP and NT-proBNP in HF patients discharged after hospitalization caused by HF or myocardial infarction (MI). The optimal use of copeptin in HF remains unresolved and future appropriately sized and randomized trials must determine the role of copeptin in HF as a marker of adverse outcomes, risk stratification or as a target in biomarker-guided therapy with arginine vasopressin-antagonists in individualized patient treatment and everyday clinical practice.
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
01:26Heart Failure Drugs: Inotropic Agents
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:26Heart Failure III: Clinical Manifestations